Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Listed
Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,293 across all filing types
Latest filing 2026-06-12 Capital/Financing Update
Country CN China
Listing Shanghai Stock Exchange 603658 · 1 venue

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by Zhengzhou Antu Biological Engineering Co., Ltd. regarding the use of idle raised funds (募集资金) for cash management activities. It details specific investment products purchased using idle funds from previously issued convertible bonds and non-public equity issuance. The document outlines amounts, risk analysis, approval procedures by the board, income from these cash management activities, and recent progress concerning the redemption of those products. This document primarily serves as an update and disclosure of the company's financing or capital use activities, especially regarding fund management and cash management using idle raised capital. It contains no financial statements, earnings data, or comprehensive company performance data typical of reports like Annual or Interim Reports, nor is it a transcript, remuneration report, or voting results. It also doesn't report on a transaction in own shares or a merger. It is a capital/financing update focused on the usage of funds and their investment returns. Therefore, the most appropriate classification is Capital/Financing Update (CAP). Confidence is high given the document content's focus on raised funds' management and financial product investment activity disclosures.
2026-06-12 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Regulatory Filings Classification · 85% confidence The document is a formal company announcement (“公告”) detailing the use of idle raised funds for cash management (buying CDs, repo, wealth products), the board approvals, risk controls, and progress of redemption. It is not an earnings release, proxy, dividend notice, share issue, M&A, or audit report, nor does it constitute a financial report itself. This type of compliance/regulatory announcement falls under the general “Regulatory Filings” fallback category (RNS).
2026-06-05 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Regulatory Filings Classification · 75% confidence The document is a corporate announcement detailing the company’s use of idle raised funds for cash management, including board approvals, risk analysis, and redemption progress. It does not present a full financial report (10-K, IR) nor is it announcing new financing, share issuances, dividends, or governance changes. It is a structured regulatory disclosure required by the Shanghai Stock Exchange but does not fit into more specific financing or capital-structure categories. Therefore it falls under the catch-all Regulatory Filings category (RNS).
2026-05-28 Chinese
安图生物关于使用闲置募集资金进行现金管理赎回及进展的公告
Regulatory Filings Classification · 95% confidence The document is a formal stock exchange announcement detailing the company’s use of idle raised funds for cash management (purchasing large-denomination certificates, repo, wealth products), board approvals, risk control, and redemption progress. It is not an earnings or quarterly report, not a proxy or AGM material, nor a capital raising or M&A notice. It instead represents a miscellaneous regulatory disclosure under Shanghai Stock Exchange rules. Hence it falls into the fallback category “Regulatory Filings (RNS).”
2026-05-26 Chinese
安图生物关于召开2025年度暨2026年第一季度业绩说明会的公告
Regulatory Filings Classification · 85% confidence The document is a formal announcement by the company to convene a 2025 full-year and 2026 Q1 performance briefing (业绩说明会) for investors, detailing time, venue, participation method and contact info. It does not contain the actual financial report or the presentation materials, nor is it a transcript or an earnings summary—it’s simply a general regulatory announcement about an upcoming investor event. This does not fit any specific categories like Investor Presentation (which requires the slide deck), Earnings Release (which would summarize results), or Call Transcript. Therefore it falls under the fallback “Regulatory Filings” category.
2026-05-22 Chinese
安图生物2025年年度权益分派实施公告
Notice of Dividend Amount Classification · 96% confidence The document is a public announcement by the company’s board detailing the per-share cash dividend amount for the 2025 fiscal year, the record date, ex-dividend date, payment date, total payout, and tax arrangements. It does not contain full financial statements or serve as an AGM/EGM notice beyond approving the dividend, nor is it an interim/annual report, audit report, or share issuance. This matches the definition of a Notice of Dividend Amount (DIV).
2026-05-21 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.